Trending News
News
News
AstraZeneca Returns Worldwide Rights to IPI-504 and IPI-493 Development Programs to Infinity Pharmaceuticals
The rights will enable the development and commercialization of Infinity’s heat shock protein 90 drug candidates IPI-504 and IPI-493 for cancer treatment.
News
Bristol-Myers Squibb and Exelixis Enter Global Collaboration on Two Cancer Programs
Programs include XL184, a Phase III inhibitor of MET, VEGFR2 and RET, and XL281, a Phase I Inhibitor of RAF Kinase.
News
New Data Show Zometa® Enhances Impact of Chemotherapy on Reducing Breast Tumor Size
Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies.
News
Oncolytics Biotech REOLYSIN® Exceeds Primary Statistical Endpoint in U.S. Phase 2 Sarcoma Study
The Phase 2 clinical trial has evaluated the intravenous administration of REOLYSIN® in patients with various sarcomas that have metastasized to the lung.
News
Helsinn Healthcare and Zealand Pharma Sign a Partnering Agreement for Zp1846
Helsinn receives license to ZP1846 for further development, regulatory approvals, manufacturing, marketing and sales of the compound.
News
VIVUS Initiates Avanafil Phase 3 Trials in Males with ED
The REVIVE study is a randomized, double-blind, placebo-controlled, efficacy and safety study of avanafil in men with a history of ED.
News
MorphoSys Announces Second Clinical Milestone in Therapeutic Antibody Program
MorphoSys and Centocor have enrolled a patient in a Phase 2 clinical trial with a HuCAL-derived fully human antibody.
News
Australian Cancer Research Organization CTx Choose IDBS to Protect Patent Data
CTx has selected both E-WorkBook and ActivityBase to manage its drug discovery and development on a global multi-site basis.
News
pSivida new Clinical Trial for Drug Delivery Device in AMD
The Company begins clinical trial using its Medidur™ technology to assess the safety and efficacy of Iluvien in patients with bilateral geographic atrophy.
News
AFFiRiS Begins Development of a Parkinson's Vaccine
AFFiRiS starts pre-clinical development of its first Parkinson's vaccine that will be investigated for efficacy in Parkinson models.
Advertisement